Lysteda Approved by FDA for Heavy Menstrual Bleeding
It was announced by Xanodyne Pharmaceuticals, Inc. last month that the FDA has approved Lysteda (tranexamic acid) oral tablets for treatment in women who suffer from cyclic heavy menstrual bleeding (HMB), also known as menorrhagia. This is reported to be a first of its kind oral therapeutic treatment made specifically for HMB.
Heavy menstrual bleeding affects nearly one out of every ten women in the U.S. It is one of the most common complaints doctors and gynecologists treat. HMB is described as 80 milliliters of blood loss per regular menstrual cycle. It is caused by an abnormally high rate of clot breakdown in the uterus. This condition affects the daily life of those who suffer from it, increasing time lost from school and work.
Lysteda works as an anti-fibrinolytic and keeps the menstrual clot from quickly breaking down and stopping the flow of blood normally. In clinical trials, there was a statistically significant reduction in blood loss between those who took Lysteda and those who took a placebo.
Lysteda Side Effects and Risks
Common adverse reactions to Lysteda reported by patients during clinical trials include:
- abdominal pain
- back pain
- muscle cramps
- muscle and joint pain
- sinus and nasal symptoms
Patients who are also using birth control pills may have an increased risk of blood clot, stroke, or heart attack.
If you or a loved one suffers from these or other symptoms after taking Lysteda, see your physician. If you are in the Kansas City, Missouri area, please contact the experienced pharmaceutical litigation attorneys at Schlichter, Bogard, & Denton for an initial case consultation. We also serve clients nationwide.